Advertisement

FDA Issues Draft Guidance Encouraging Inclusion of Male Patients in Breast Cancer Clinical Trials


Advertisement
Get Permission

A draft guidance issued by the U.S. Food Drug Administration (FDA) on August 26 includes draft recommendations for the inclusion of male patients in breast cancer clinical trials.

Historically, males either have not been included in clinical trials for drugs to treat breast cancer, or inclusion of males in those trials has been very limited; when finalized, the draft guidance will provide clarity for industry regarding clinical development of drugs to treat breast cancer in male patients.


“We hope that the recommendations in the draft guidance…will, when finalized, encourage drug development for the treatment of male breast cancer, and ultimately, provide additional FDA-approved treatment options for patients.”
— Richard Pazdur, MD

Tweet this quote

“Less than 1% of all breast cancer cases occur in men, but men are more likely to be diagnosed at an older age and have a more advanced stage of disease. As breast cancer in men is rare, they have typically not been included in clinical trials for breast cancer treatment. This has led to a lack of data, so their treatment is generally based upon studies and data collected in women. While some FDA-approved treatments are [sex]-neutral in their indication, many therapies are only approved for women and further data may be necessary to support labeling indications for men…we issued a draft guidance encouraging the inclusion of male patients in breast cancer clinical trials. When finalized, the recommendations in the draft guidance will provide clarity for industry regarding how additional data to support efficacy and safety for male patients with breast cancer can be generated through a variety of trial designs using different data sources, including studies using real-world data,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “We hope that the recommendations in the draft guidance…will, when finalized, encourage drug development for the treatment of male breast cancer, and ultimately, provide additional FDA-approved treatment options for patients.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement